WILMINGTON, N.C. (April 17, 2008) - PPD, Inc. (Nasdaq: PPDI) today announced it has received the CEO Cancer Gold Standard™ accreditation from the CEO Roundtable on Cancer, recognizing the company's efforts to reduce cancer risks among employees and improve their overall health.
"According to the National Cancer Institute, cancer is the second-leading cause of death in the United States," said Fred Eshelman, chief executive officer of PPD. "As a company committed to helping our clients find life-saving therapies for debilitating diseases such as cancer, it is extremely important that we work to educate all of our employees about cancer risks and provide them with resources to enhance their health. We are honored that the CEO Roundtable on Cancer has recognized our achievements with this prestigious accreditation."
The accreditation recognizes PPD's commitment to creating and implementing programs aimed at educating employees on reducing their cancer risks by discouraging tobacco use, encouraging physical activity, and teaching healthy diet and nutrition. In addition, PPD has informed employees about early cancer detection and provided information on accessing quality care and clinical trials.
"I am pleased and honored to confirm PPD's status as a Gold Standard organization," said William Weldon, chairman and chief executive officer of Johnson & Johnson and chairman of the CEO Roundtable on Cancer. "PPD's leadership will pave the way to help us extend the reach of this life-saving program as many more organizations work to adopt the Gold Standard in future years."
The CEO Roundtable on Cancer was founded in 2001 when former President George H. W. Bush challenged a group of executives, led by Robert A. Ingram, then CEO of Glaxo Wellcome, now GlaxoSmithKline, to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded with the CEO Cancer Gold Standard and have since collaborated with the American Cancer Society to encourage its widespread adoption in work places across the country. For more information about the CEO Roundtable on Cancer, visit www.ceoroundtableoncancer.org.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,200 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the CEO Cancer Gold Standard accreditation, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; rapid technological advances that make our products and services less competitive; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
Sue Ann Pentecost
+919 456 5890
+910 558 7585